Boobalan Pacha's questions to Addex Therapeutics (ADXN) leadership • Q1 2023
Question
Boobalan Pacha of H.C. Wainwright & Co. inquired about the implications of the positive recommendation to continue the Phase II trial for ADX-71149 and asked for an update on partnership efforts for Dipraglurant.
Answer
Executive Timothy Dyer explained that the recommendation from the independent review committee to continue the ADX-71149 study is very positive, suggesting the drug is safe and potentially effective, which increases the probability of a successful outcome. Regarding Dipraglurant, he confirmed that discussions with multiple potential partners are ongoing across the entire portfolio, but could not provide specific details on progress.